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Abstract
A deficiency in blood coagulation factor VIII (fVIII) is responsible for the inherited
bleeding disorder hemophilia A, which affects approximately 1 in 5000 males. The
development of inhibitory antibodies is a significant issue faced by hemophilia A
patients receiving therapeutic infusions of fVIII. The C-terminal C2 domain of fVIII has
been shown to be highly immunogenic and the site of binding for numerous
antibodies of both the classical and non-classical classifications. A detailed
understanding of the structural components involved in C2-antibody binding
interactions is vital for the development of improved therapeutics for hemophilia
patients. Here we present the structure of the classical antibody 3E6 bound to
human C2 at 2.6 Å resolution. Previous studies have suggested that pairs of classical
and non-classical antibodies may exhibit binding cooperativity. Comparison of the
C2:3E6 structure with a previously determined ternary structure of C2 bound
simultaneously to both 3E6 and the non-classical antibody G99 reveals that
cooperativity is not the result of dramatic conformational changes at the binding
interface. Rather, changes in B-factor ratios between the C2 complexes and the
isolated C2 domain suggest that dynamic changes upon 3E6 binding may lead to
more favorable binding of a second antibody on the protein’s opposite face. Studies
of the fVIII C2 domain were then extended to attempts to understand the structural
basis for the interactions between fVIII and its circulatory partner von Willebrand
iv

factor (vWF), which is crucial for maintaining fVIII levels in plasma. The inability for
vWF to bind fVIII is the basis for another blood coagulation disorder, von
Willebrand’s disease type 2N, which can lead to hemophilia-type levels of fVIII in the
blood and subsequent bleeding episodes. Previous publications have suggested a
role for C2 in the binding of vWF. Attempts were made to formulate protein
complexes between two vWF domain mutants, TIL'E' and D'D3, and the human C2
domain, but were ultimately unsuccessful. This outcome corroborates recent
publications suggesting that the fVIII C1 domain may play a more active role in
binding vWF than the C2 domain. In order to further study this possibility, complexes
were formed between recombinant B-domain deleted fVIII and TIL’E’ or D’D3 and Xray crystal trials initiated. Hopefully, greater understanding of the structural
interactions between fVIII and other proteins will lead to improved therapies for
patients suffering from fVIII-related diseases.
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Background: Blood Coagulation and the Role of FVIII
Following vascular injury, excessive blood loss is prevented by the regulated reaction
cascade of blood coagulation, or hemostasis. This highly conserved, multistep process
acts rapidly at the site of tissue damage to halt potentially fatal bleeding. Hemostasis
consists of three primary steps: vasoconstriction, platelet plug formation, and the
formation of a fibrin clot. Vasoconstriction, or the narrowing of the blood vessels, is the
first route to prevent blood loss, and is particularly key in slowing hemorrhage from
arteries and large vessels. This is followed by the formation of a platelet plug, also
known as a soft clot. Platelets are non-nucleate cells produced by megakaryocytes in the
bone marrow that circulate in the bloodstream in their inactive form.1 Upon vascular
damage, they undergo biochemical and morphological changes to become active,
allowing them to adhere not only to each other, but also to exposed subendothelial
collagen and subsequently form the initial clot.2 The final step in clot formation, the
production of a fibrin mesh that supplements the aggregated platelets, is the result of a
complex pathway known as the blood clotting cascade. In this process, a host of
proteins know as clotting factors act in concert to ultimately produce insoluble fibrin
from its soluble precursor fibrinogen, thus strengthening the clot and allowing normal
wound healing processes to occur.

Intrinsic vs. Extrinsic Pathway
There are two pathways in coagulation that have different initial triggers but the same
ultimate goal: the production of insoluble fibrin from its soluble precursor fibrinogen.
Traditionally, the extrinsic pathway, or tissue factor pathway, is believed to be the most
rapidly initiated pathway, responsible for an initial burst of thrombin activation, while
the intrinsic pathway is necessary for a prolonged and sustained amplification of clotting
activity.3 These two pathways converge on what is known as the final common pathway,
in which thrombin is produced by activated factor X (fXa) and in turn cleaves fibrinogen
into fibrin (Figure 1). Thus, it is only in the steps leading to the activation of fX to fXa
that the pathways differ.
Damaged Surface

Trauma

XIIa

XII
XI

VIIa

XIa
IX

IXa

VIII

TF

VIIIa
X

VII

X

Xa
V
Prothrombin

Va
Thrombin

Fibrinogen

Fibrin
XIIIa

XIII

Cross-linked
Fibrin Clot

Figure 1. Blood coagulation cascade. The intrinsic pathway is shown in the red box, with
the extrinsic pathway in the green. Both feed into the final common pathway and lead
to the production of cross-linked fibrin mesh to supplement the platelet soft clot.
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The extrinsic pathway begins with the exposure of an extravascular cell surface receptor
called tissue factor to the bloodstream via vascular damage. This transmembrane
protein serves as a cofactor to the serine protease fVII, which circulates constitutively in
the bloodstream.4 Together, this complex activates the serine protease fX, either by a
direct cleavage event, or by the intermediary path of activating fIX, which in turn can
proteolytically activate fX.5 This leads to the common pathway processes of thrombin
activation by fXa and subsequent formation of the insoluble fibrin mesh.

Table 1. Selected blood coagulation factors. Pathway, molecular weight, and function of
plasma proteins are listed.
Factor
Name
Pathway MW (kDa) Function
I
Fibrinogen
Both
340
Zymogen
II
Prothrombin
Both
72
Zymogen
III
Tissue Factor
Extrinsic
44
Cofactor
IV
Calcium Ions
Both
V
Proaccelerin; Labile Factor
Both
330
Cofactor
VII
Proconvertin; Stable Factor
Extrinsic
50
Zymogen
VIII Antihemophilic Factor A
Intrinsic
285
Cofactor
IX
Christmas Factor; Antihemophilic
Intrinsic
57
Zymogen
Factor B
X
Stuart-Prower Factor
Both
59
Zymogen
XI
Plasma Thromboplastin Antecedent
Intrinsic
160
Zymogen
(PTA)
XII
Hageman Factor
Intrinsic
76
Zymogen
XIII
Fibrin-stabilizing Factor
Both
320
Zymogen
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By contrast, the intrinsic pathway, thus named because all of the components are
already present internally in the bloodstream, begins with the activation of factor XII,
which is initiated when this protein comes into contact with negatively charged
surfaces.6 fXIIa is a serine protease that is responsible for the activation of fXI to fXIa,
which in turn proteolytically activates fIX. Activated fIX forms a complex with factor VIIIa
(fVIIIa), one of the non-protease members of the blood coagulation cascade, that binds
activated platelet surfaces and serves as a cofactor to fIXa in the proteolytic activation
of fX (Figure 2). fXa forms a complex with its cofactor fVa, which has high sequence
homology to fVIII and similarly serves to anchor the complex to the membrane.7 This
complex is responsible for converting prothrombin into its active form, thrombin, which
participates in a number of amplification feedback loops and ultimately cleaves soluble
fibrinogen into insoluble fibrin. These fibrin monomers polymerize into the strong mesh
that is responsible for supplementing the platelet plug to form a stable blood clot. The
covalent cross-linking reaction results in the formation of an isopeptide bond between
adjacent fibrin monomers and is catalyzed by active factor XIII (fXIIIa), which is also
activated by the proteolytic action of thrombin.

4

fX

Ca2+

fIXa

fVIIIa
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fVIII

fVa
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Prothrombin

VWF

thrombin

Fibrinogen

Fibrin

Figure 2. Role of fVIII in blood coagulation. After dissociating from its circulatory
partner, von Willebrand factor (vWF), fVIIIa binds to phosphotidylserine (PS)-expressing
membranes and serves as a cofactor to serine protease fIXa in the proteolytic activation
of fX.

Factor VIII
Coagulation fVIII is a 2,332-residue glycoprotein that is produced in multiple tissues in
the body, including the liver, spleen, and kidneys.8 It is expressed with the domain
arrangement of A1-A2-B-A3-C1-C2 prior to proteolytic processing and initially undergoes
extensive glycosylation in the lumen of the endoplasmic reticulum and Golgi complex
(Figure 3).9-12 The three A domains have been found to exhibit approximately 30%
5

sequence homology to each other as well as to the copper binding protein
ceruloplasmin.13 The two C domains also have extensive homology to each other.9 In
contrast, the B domain shows no known homology to other proteins. This domain
undergoes proteolytic cleavage early in the fVIII life cycle at residues Arg1313 and
Arg1648, thus forming a noncovalently associated heterodimer consisting of a heavy
chain (A1-A2-B) and a light chain (A3-C1-C2) (Figure 4).14

Figure 3. Domain arrangement of FVIII. While initially expressed as a single chain,
following proteolytic processing of the B domain, FVIII is secreted as a heterodimer.
The active form of the protein is a heterotrimer following cleavage by fXa or thrombin.

FVIII circulates in the bloodstream in this inactive form, noncovalently bound to the
glycoprotein von Willebrand factor (vWF). This interaction prevents the breakdown of
fVIII in circulation and is also thought to prevent premature binding of fVIII to fIXa and
6

activated platelet surfaces.15,16 Previous data suggests that two regions of the fVIII light
chain are essential for vWF binding: the acidic region of the A3 domain corresponding to
residues 1649-1689 and the carboxyl terminus of the C2 domain.17 Additionally, the fVIII
light chain is also responsible for membrane binding, with the current working model
indicating that solvent exposed, hydrophobic residues present on the beta hairpin loops
of C2 embed within the membrane, while a ring of positively charged residues nearby
interacts with the negatively charged phospholipid headgroup of phosphatidylserine
(PS), thereby stabilizing the interaction.18

A2
A1
A3

C2

C1

Figure 4. X-ray crystal structure of B-domain deleted fVIII. Depicts the A1 (blue), A2
(cyan), A3 (orange), C1 (yellow), and C2 (red) domains.11
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Following vascular damage, fVIII undergoes proteolytic activation by thrombin or factor
Xa to form a heterotrimer (A1/A2/A3-C1-C2).19,20 Thrombin cleaves fVIII at three sites,
Arg1689 within the light chain and Arg372 and Arg740 in the heavy chain, while fXa
cleaves at Arg336, Arg372, and Arg740.14 Activated fVIII (fVIIIa) dissociates from vWF
and binds to activated platelet surfaces, where, in the presence of calcium ions, it serves
as a cofactor for serine protease factor IXa. This complex, known as the intrinsic
"tenase" complex, is responsible for converting fX to fXa at an increased rate of
approximately 200,000-fold.19, 21
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Part I Introduction: Hemophilia A and Inhibitory Antibodies

Hemophilia A
Hemophilia A is a blood clotting disorder caused by a lack of the blood coagulation
protein factor VIII (fVIII). Congenital hemophilia A, which varies in severity depending on
the amount of functional fVIII present, is an X-linked disorder affecting 1 in 5000 males
worldwide.22,23 The disorder is characterized by frequent and prolonged bleeding
episodes in which the blood fails to clot properly. Often, patients also suffer from
excessive bruising and painful swelling in the joints due to accumulation of blood from
internal bleeds. The severity of the disease is categorized according to the amount of
functional fVIII present; mild hemophilia A is defined as 6-30% normal factor activity,
moderate as 1-5%, and severe cases as less than 1% normal factor activity.24 The 186 kb
gene encoding the fVIII protein, F8, is located on the long arm of the X-chromosome25
and is the site of over 2,500 unique mutations known to cause hemophilia A.26
Mutations leading to the disorder can occur throughout the gene and include intron
inversions, insertions, deletions, nonsense and missense mutations.27, 28

9

Hemophilia A Treatment
The primary treatment for the disease is infusions of functional fVIII. 29,30 Previously, this
fVIII was mainly human plasma-derived, but in recent years recombinant products have
taken over as the principal source of fVIII for infusions. Patients with severe cases of
hemophilia A often receive prophylactic infusions 2-3 times per week, as well as ondemand therapy for emergency situations. However, treatment is complicated by the
development of neutralizing inhibitory antibodies directed against the infused fVIII.
Approximately 30% of patients receiving replacement therapy develop inhibitory
antibodies, an immune response leading to the clearance of fVIII from circulation and
continued lack of clotting function, which persists long term.31-33 Although the immune
response occurs in patients with mild to severe disease states, it has been noted that
patients with more severe genetic lesions such as nonsense mutations, inversions, and
large deletions that lead to the production of no endogenous fVIII often suffer from
more severe immune response, possibly because the body does not recognize fVIII as
self.34

One treatment option used to overcome this inhibitory response is immune tolerance
induction, or ITI. Although the exact protocols employed differ, the basis of ITI is in
10

giving patients very large doses of fVIII, sometimes accompanied by immunosuppressive
drugs or other proteins, for prolonged periods of time to eventually abolish the immune
response.35 As there is no one method of ITI that is effective for all patients, there are
extensive differences in the dosing schedule and amount of fVIII needed to induce
immune tolerance.36 Due to the high levels of fVIII often required, this treatment option
is often cost prohibitive. Additionally, it is not successful in approximately 25% of cases,
leading to the ongoing need for additional treatment options for hemophilia A patients
suffering extensive inhibitory response.37

A number of strategies have been employed to produce less immunogenic fVIII that
maintains a longer half-life in circulation. One such method is chemical modification in
the form of PEGylation. The addition of polyethylene glycol polymers to therapeutic
proteins has been shown to increase circulation time by “masking” the molecule from
the immune system and reducing clearance by the kidneys.38 Fusion proteins represent
another category of fVIII therapeutics currently in clinical trials. Two such strategies are
the fusion of fVIII molecules to either the Fc fragment of human immunoglobulin G (IgG)
or to albumin, both of which increase half-life by binding to the neonatal Fc-receptor,
which prevents degradation and recycles the proteins back into circulation.39
Stabilization of fVIII via modification of the protein sequence itself is another tool for
11

increasing circulation half-life. Deletion of the B-domain coupled with covalent linkage
of the heavy and light chains of the heterodimer via an engineered disulfide bond
between the A2 and A3 domains was shown to increase stability by preventing the
possibility of dissociation of the molecule at the A2 domain.40,41 Furthermore, it was
demonstrated that mutations of certain residues at the interfaces of A2 with the A1 and
A3 domains to decrease charge and increase hydrophobicity yielded fVIII molecules that
were both more thermally stable and less prone to dissociation.42

FVIII and Inhibitory Antibodies
In order to produce improved therapeutics, detailed knowledge of the structural
interactions between fVIII and inhibitory antibodies is vital. First, a brief consideration of
immunoglobulin G (IgG) structure is necessary. IgG molecules have a distinctive Y-shape
that is composed of two heavy chains and two light chains, which are identical to each
other respectively (Figure 5). There are two distinct types of fragments of the antibody,
the Fc, or constant fragment, and the antigen binding fragment, FAB. Each antibody
contains two FABs, which are located at the tips of the molecule’s “arms” and are
responsible for binding to the antibody’s target, or antigen. While the FC region of the
antibody is conserved throughout its class, the FAB is highly variable, thus allowing it to
bind to its target with exquisite specificity. Each FAB contains two variable domains, one
12

from the light chain and one from the heavy chain, each of which, in turn, contains three
complementarity determining regions (CDRs), highly variable loops that recognize
specific regions of the antigen called epitopes. The two FABs can be separated from the
FC domain through proteolytic cleavage by the enzyme papain, isolated from papaya,
thus allowing for the study of antibody-antigen interactions using individual FABs bound
to their target proteins.

Figure 5. Schematic of antibody structure. The antibody consists of two heavy chains
(dark blue) and two light chains (light blue), and is divided into an antigen binding
fragment (FAB) and constant fragment (FC).

13

Characterization of the immune response to fVIII has revealed that the A2 and C2
domains are the sites of the majority of epitopes recognized by antibodies against
fVIII.43 Antibodies against the C2 domain are broadly categorized into two classes based
on their mechanism of inhibiting fVIII function. Classical antibodies are defined as those
which block the binding of the C2 domain to vWF or phospholipid surfaces, which have
been demonstrated to involve partially overlapping sites on C2.44-46,17 Conversely, nonclassical antibodies prevent the activation of fVIII by thrombin or factor Xa and comprise
the majority of fVIII C2 domain inhibitors.47-49

Detailed structural studies of the C2 domain in complex with inhibitory antibodies have
allowed the characterization of both classical and non-classical epitopes in recent
years.50,51 A recent X-ray crystal structure of the C2 domain bound simultaneously to
antigen binding fragments of both a classical and non-classical antibody demonstrated
that these inhibitors bind to opposite faces of the protein (Figure 6).52

14

Figure 6. X-ray crystal structure of the fVIII C2 domain ternary complex. The C2 domain
is bound in complex with a classical antibody FAB (3E6) and non-classical FAB (G99),
which bind on opposite faces of the C2 domain.49

The classical antibody 3E6 was shown to sequester residues implicated in vWF binding,
including Lys2183, Asp 2187, and Arg2215.52 The epitope of non-classical antibody G99,
however, was demonstrated to consist partially of residues involved in binding to both
factors IXa and Xa.52 While 3E6 was not shown to bind the solvent exposed hydrophobic
loops implicated in phospholipid binding, the X-ray crystal structure of another classical
antibody, BO2C11, in complex with C2 revealed that this inhibitor's variable region
completely occludes the hydrophobic loops, preventing the key membrane binding
function of C2.53 Thus, different antibodies falling under the same broad "classical"
definition are seen to prevent C2 function in different ways. A 2014 study by Nguyen et
al. used surface plasmon resonance (SPR) to map the epitopes of a panel of anti-C2
antibodies, building on previous work that defined subcategories of binding for classical
15

and non-classical inhibitors.54,47 Three distinct clusters of residues have been identified
that correspond to five different antibody types, A, B, C, AB, and BC, which bind either
exclusively to A, B, or C, or in an overlapping fashion to the AB or BC epitope regions.47

In light of the C2-3E6-G99 ternary structure, some questions remain. Interestingly, as
mentioned previously, the 3E6 epitope does not include the hydrophobic loops that are
believed to embed in the phospholipid membrane upon fVIII binding. Thus, questions
about how 3E6 exerts its neutralizing effects remain. One hypothesis presented by
Walter et al. in the ternary structure paper is that long-range electrostatic changes
occur upon antibody due to charge neutralization in the binding region.52 Additional
structural data of the C2-E36 binding interactions could provide further insight into the
mechanism of inhibition by this classical antibody. Aside from the interactions of 3E6
alone, unpublished data has suggested that the classical and non-classical antibodies
bind cooperatively to their fVIII target. Subsequently, in hopes of elucidating some of
these remaining structural questions, we aim to solve crystal structures of the binary
complexes C2-G99 and C2-3E6 for comparisons with the C2-3E6-G99 ternary structure.

16

X-ray Crystallography
To study the structural characteristics of the fVIII protein complexes, X-ray
crystallography was employed. X-ray crystallography is a structural technique that
allows for the construction of an atomic-resolution model of macromolecular structure.
The data for building these models is obtained from the diffraction of X-rays by many
identical molecules in the ordered array of a crystal. These diffracted X-rays produce a
pattern of spots, called reflections, on a detector. From this diffraction pattern, it is
possible to determine the positions of the atoms that gave rise to the data. Specifically,
because it is actually the electrons within the molecule that are scattering the X-rays,
the diffraction pattern allows for the calculation of an electron density map into which
can be modeled the amino acid residues from the known protein sequence.

The ability to produce an effective model using X-ray crystallography is contingent upon
producing high quality protein crystals for diffraction. This process is often the limiting
step of using X-ray crystallography to determine protein structure. In order to
encourage proteins to crystallize, vapor diffusion is most commonly employed. In this
technique, a drop of protein solution is mixed with a drop of buffer solution containing a
precipitant and then allowed to equilibrate with a larger reservoir solution. Because the
reservoir contains a comparatively higher concentration of the precipitant, water vapor
17

slowly diffuses out of the protein droplet, thereby increasing the protein concentration
in a gradual manner. Proteins, as with other molecules, can be encouraged to form
crystals in supersaturated solution, which is facilitated by the vapor diffusion process.

A suitable crystal is then frozen in liquid nitrogen, placed into a monochromatic X-ray
beam, and slowly rotated while being irradiated to collect a complete data set, which
can then be used to generate an electron density map. The intensities of the waves
scattered by the electrons in the crystal comprise the data that is measured. However,
while the amplitude of these waves can be measured from the data, information
regarding the phase of the waves is lost. This constitutes what is known in X-ray
crystallography as "the phase problem."55 In order to solve the phase problem, three
primary techniques are used. The first of these is multiple isomorphous replacement, in
which heavy atoms derivatives of the protein are prepared and used to generate a
diffraction pattern. Small perturbations in the heavy atom diffraction pattern versus
that of the original crystal allow for the estimation of the phases.55 Another common
phasing method is multiple-wavelength anomalous dispersion (MAD). This method also
takes advantage of heavy atoms in the crystal, in this case by taking advantage of the
heavy atoms' ability to absorb X-rays of certain wavelengths and then reemit the
radiation with an altered phase, leading to an anomalous scattering signal.56 Finally,
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there is molecular replacement, which has become the most common form of phasing.
In this method, the crystallographer uses homologous structures to the protein under
consideration to computationally determine the phases. Molecular replacement is the
method employed in this study, as structures of the fVIII C2 domain and antibodies
already exist. Following the determination of the phases, iterative cycles of model
building and refinement can be used to construct a model that best fits the
experimental data collected and elucidate structural questions.
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Part 1: Research Aims
The goal of the presented research was to gain insights into the structural basis for
interactions between the fVIII C2 domain and inhibitory antibodies. Specifically, we
sought to elucidate the basis for antibody binding cooperativity that has been observed
previously. To accomplish these goals, we first employed X-ray crystallography to
determine the structure of the C2 domain bound in complex with classical inhibitory
antibody 3E6.

Following determination of this binary complex structure, we compared this structure to
a previously determined ternary structure of the C2 domain bound simultaneously to
3E6 and the non-classical inhibitory antibody G99. The objective of these structural
comparisons was to ascertain if differences between the binary and ternary complexes
could answer our questions about binding cooperativity and structural conservation
among different complexes of C2 and inhibitory antibodies.
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PART I: MATERIALS AND METHODS
C2-3E6 Complex Preparation
Purified 3E6 FAB was incubated with a 1.5X molar excess of purified human C2 domain
for 30 minutes at room temperature. Immediately after incubation, this sample was
applied to HiLoadTM 16/60 Superdex 75 preparatory grade size exclusion
chromatography column (120 mL column volume, GE Healthcare), which was attached
to an AKTAprime Plus compact liquid chromatography system (GE Healthcare) and
equilibrated in C2 low salt buffer (50 mM NaCl, 20 mM Tris-HCl (pH 8.0), 2.5% (v/v)
glycerol). The eluent was collected and concentrated for SDS-PAGE analysis prior to Xray crystallography trials.

Data Collection and Structure Determination
Hanging drop vapor diffusion was employed to produce crystals of adequate size for Xray diffraction. Sparse matrix screens were optimized to encourage crystal growth.
Crystals were grown in reservoir condition of 10mM MES, pH 6.5, and 20% (w/v) PEG
8000, and flash frozen using the same solution with the addition of 30% (v/v) DMSO as a
cryoprotectant. X-ray diffraction data was collected at the Fred Hutchinson Cancer
Research Center in Seattle, WA, on a Rigaku Micromax-007HF rotating anode with
Confocal Varimax Optics Systems and an RAXIS-IV++ imaging plate detector. Diffraction
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data was collected with CrystalClear (Rigaku), and indexing, scaling, and integration
were accomplished with HKL2000. Initial phases were determined by molecular
replacement with PHASER using the C2 domain (PBD: 1D7P), the variable region of the
3E6 FAB (PBD: 4KI5), and the constant region of the 3E6 FAB as search models. Model
building and refinement were accomplished in iterative cycles with WinCoot and
PHENIX, respectively.
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Part I: Results
To further understand the complex interactions between the fVIII C2 domain and
inhibitory antibodies, X-ray crystallography trials of the C2:3E6 binary complex were
undertaken. Sparse matrix conditions were optimized to produce the final, successful
result in 10 mM MES (pH 6.5) and 20% (w/v) PEG 8000. Crystals were allowed to grow
by vapor diffusion over multiple months of incubation time. The successful data set, in
which the crystal diffracted to 2.6 Å, was acquired following approximately one year of
undisturbed incubation. Molecular replacement was used to solve the phase problem,
taking advantage of previously solved structural information for both C2 and the 3E6
FAB. Following initial processing, it was determined that there were two copies of the
complex (two C2 domains, each bound to a 3E6 FAB) present in the asymmetric unit.
Thus, it was necessary to independently construct the two biological assemblies during
the model building and refinement process.

Following the initial processing and phasing, model building and refinement were
carried out in iterative cycles using the programs WinCoot and PHENIX, respectively.57,58
In this process, the model was examined residue by residue to identify areas of electron
density that differed between the model and the experimental data. Adjustment of
residue position or orientation was utilized to better fit the model to the data, as well as
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altering bond angles or individual rotamers (Figure 7). Each cycle of model building was
then followed by one or more rounds of refinement using PHENIX. In later rounds of
building, water molecules were modeled into areas of density present experimentally
but not occupied by the model. Both experimental density and consideration of
distances conducive to hydrogen bonding with nearby atoms were taken into account in
the placement of 241 water molecules throughout the structure. Additionally,
correction of Ramachandran outliers was undertaken as the model refinement
continued. Following approximately 45 rounds of building and refinement, the model
was completed and, at the time of writing, has been deposited into the Protein Data
Bank (PDB) pending publication, with the PDB ID 4XZU.

Figure 7. Density Map. Example of an electron density map and corresponding residues
from WinCoot during the model building process.
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Refinement statistics of R-work and R-free were monitored throughout the refinement
process. R-work, also known as R-factor, is a measure of the quality of the model. During
the refinement process, the atomic model is used to calculate an electron density map,
which is then compared to the experimentally determined electron density. The R-work
describes how closely these two are in agreement. However, this process introduces an
element of bias in that the atomic model and electron density are used to calculate the
new electron density. The circularity of this process can lead to over-fitting of the
model. To counter this bias and assess the validity of the model, another statistic,
known as R-free, is calculated.59 R-free is calculated in the same manner as R-factor but
uses a small subset of residues that are set aside and not used in refinement. R-free is
then a measure of how well the current model predicts the experimental data from this
portion of the data set that is unbiased. While the R-free is often significantly higher
than the R-work early in the model building process, they should become more similar
as refinement is accomplished.
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Table 2. Crystallographic data and refinement statistics from C2:3E6 structure.
Data Collection Statistics
Wavelength (Å)
Resolution range (Å)
Space group
Unit cell (Å, °)
Total reflections
Unique reflections
Multiplicity
Completeness (%)
Mean I/sigma(I)
Wilson B-factor
R-merge
Refinement Statistics
Resolution (Å)
R-work
R-free
Number of non-hydrogen atoms
macromolecules
ligands
water
Protein residues
RMS bonds (Å)
RMS angles (°)
Ramachandran
favored (%)
allowed (%)
outliers (%)
MolProbity Clashscore
Average B-factor (Å2)
macromolecules
ligands
solvent
PDB code

1.54
39.77 - 2.609 (2.702 - 2.609)
P 2 21 21
a = 43.23, b = 148.49, c = 188.42,
α = β = γ = 90
211,017
36,886 (3,537)
5.7 (5.8)
96.86 (93.47)
15.20 (6.08)
48.03
0.067 (0.292)

40 – 2.61 (2.68 – 2.61)
0.1988 (0.2500)
0.2673 (0.3491)
9,034
8,790
3
241
1,137
0.011
1.36
91
8.2
0.8
12.62
49.4
49.6
70.1
41.1
4XZU
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The final values of R-work and R-free for the C2:3E6 structure were lowered to 0.1988
and 0.2673, respectively, from initial values of 0.2500 and 0.3491. The following
additional model validation parameters were also verified: bond root mean squared
deviation (RMSD), angle RMSD, clashscore, and average B-factors. Bond RMSD describes
the root mean squared deviation of the bond lengths from accepted values. Similarly,
angle root mean squared deviation is a measure of how angle distances differ from
standard values. The clashscore describes the overlap of nearby atoms’ electron density,
with greater than 0.4 Å overlap calculated as a clash by PHENIX. The “average B”
parameter represents an average of the B factors within the model to allow for a more
globalized comparison. B-factors, also called temperature factors, describe the
scattering of electrons by each atom due to thermal motion. In general terms, it is used
as a description for the dynamic mobility of each atom in the structure. An unusually
high B-factor can also be an indicator of an error in model building, which is the
reasoning behind an examination of B-factors in model validation. The average B for the
C2 3E6 structure was 49.4 Å2 overall; individual B-factor values will be discussed further
below.

Following the completion of the model, detailed analysis of the structure was
undertaken (Figure 8). The C2 domains from each of the two complexes in the
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asymmetric unit were well-resolved and consist of fVIII residues Cys2174-Glu2327 with
no omissions within these residues. The C2:3E6 binding interfaces for each of the two
complexes were similarly well-resolved and able to be modeled unambiguously into the
electron density. Of the two 3E6 FABs, that from one of the complexes (designated
Complex 1 and consisting heavy chain A and light chain B in the model) was well defined
except for heavy chains residues 132-133, which were omitted from the final model. The
FAB from the second complex (Complex 2, consisting of heavy chain E and light chain F in
the model) was less well defined and contained a number of areas of poor electron
density, specifically the absence of residues 130-135 and 177 from the heavy chain and
106, 149-154, 187-191, and 198-203 from the light chain. Importantly, as noted above,
none of these residues were near the binding interface, which was the focus of most
structural comparisons.
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FAB

Figure 8. X-ray crystal structure of the C2-3E6 binary complex A) Both copies of the
complex in the asymmetric unit, including their orientation during the modeling process.
The C2 domains of each biological assembly are shown in red and blue, while their
corresponding FABs are shown in magenta and cyan, respectively B) 90° rotation from
the view in (A), showing the orientation of each assembly with respect to the other.

Interestingly, a comparison of the two copies of the complex within the asymmetric unit
reveals that while considerable overlap exists between the structures, the FAB elbow
angle, which separates the constant and variable portions of the FAB, is significantly
different between Complex 1 and Complex 2 (Figure 9).
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Figure 9. Overlay figure of the two copies of C2:3E6 in the asymmetric unit (blue and
red, respectively) with the C2:3E6 portion of the ternary structure (green). The dramatic
difference in elbow angle between the two copies of the binary complex is illustrated in
(A), while (B) emphasizes the overall structural conservation between the binary and
ternary complex models.

This variation, while not uncommon for FAB structures, is a fairly dramatic example of
the dynamic flexibility of antibody structure that allows them to bind targets with such
exquisite precision. Aside from this angle variation, overlay of the structures reveals that
the variable regions of Complex 1 and Complex 2 are highly conserved, particularly in
the C2:3E6 interface. Furthermore, very little difference is noted between the binding
interface of each binary complex and that of the previously determined C2:3E6:G99
ternary complex. Following superposition of the binary and ternary complexes, the
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RMSD of the Cα atoms between C2:3E6:G99 and binary complexes 1 and 2 were
calculated to be 0.328 and 0.383 Å, respectively.

A closer examination of the C2:3E6 interface reveals that the antibody epitope is
discontinuous, with 3E6 sequestering two loops of the C2 domain, largely consisting of
residues Glu2181-Ala2188 and Thr2202-Arg2215. Of these two loops, seven residues
seem poised to make direct protein-antibody contacts based on distances. These
residues are Lys2183, Asp2187, Arg2209, His2211, Gln2213, Gly2214, and Arg2215
(Figure 10). Of these residues Lys2183, which is within hydrogen bonding distance of
Trp90, Tyr93, and Ser91 of the FAB, and Gln2213, which is similarly near to FAB residues
Ser33, Thr30, and Thr53, are particularly occluded by antibody binding. The 3E6 FABs
from the binary complexes bury a similar amount of surface area to that of the
C2:3E6:G99 ternary structure, which was calculated to be 690 Å2 by Walter et al.52
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Figure 10. Overlay figure of C2:3E6 binary and C2:3E6:G99 ternary complexes showing
key residues at the C2-3E6 interface. Colors: Green, ternary complex; blue/cyan, binary
complex 1; and red/magenta, binary complex 2. Right: interactions between Asp2187
and Arg2209 with 3E6 residues are conserved in both binary and ternary complexes.
Left: His2211 through Arg2215 are part of a C2 loop that is strongly occluded by 3E6
binding.

As noted above, comparison of the C2:3E6 binary structure with the C2:3E6:G99 binary
structure is surprising not for any structural changes but for the lack thereof: the two
structures show remarkable similarity when overlaid. Interactions detailed above for the
C2:3E6 binary structure are similarly demonstrated in the ternary complex. As in the
ternary structure, residues Lys2183 and Asp2187, each of which is believed to be
important for vWF binding, are occluded by the binding of 3E6, which is in keeping with
the definition of 3E6 as a classical antibody, as these inhibitors interfere with C2 binding
of vWF or phospholipid surfaces. One interesting difference between key interface
residues, however, is the positioning of Arg2215. As seen in Figure 11, in the ternary
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structure this residue makes two key salt bridges with Asp100 of 3E6. However, in the
two copies of the binary structure, we see that in Complex 1 (shown in blue), only one
of these salt bridges is maintained due to differences in Arg2215 position, while in the
other binary structure, Complex 2 (shown in magenta), neither of these interactions is
maintained.

Figure 11. Overlay figure of C2:3E6 binary and C2:3E6:G99 ternary complexes showing
variation in the position of Arg2215. In the ternary complex (green), Arg2215 makes two
salt bridges with Asp100 of the 3E6 FAB. In complex 1 of the binary complexes (blue),
only one of the salt bridges is possible due to the altered position of the residue, while
in complex 2 (magenta), neither interaction is possible.

Upon determination of the ternary structure, Walter et al. noted that, surprisingly, 3E6
does not occlude the hydrophobic loops containing Met2199-Phe2200 and Leu2251Leu52, which are believed to be key for anchoring C2 into the phospholipid
membrane.52 This is seen as well in the binary structure, which recognizes a
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discontinuous epitope that does not include these residues. Walter et al. proposed that,
rather than direct interaction with these loops, long-range electrostatic changes upon
antibody binding inhibit proper association of C2 with the membrane.

The considerable similarities between the C2:3E6 binary structure and the C2:3E6:G99
ternary structure suggest that the binding cooperativity noted previously between the
G99 and 3E6 antibodies (P. Lollar and S.L. Meeks, unpublished results) is not the result
of drastic conformational changes in the binding interface. This leads to the
consideration of other possible contributors to this cooperative behavior, specifically
electrostatic or dynamic changes. To understand electrostatic contributions, pKa
calculations for the C2 domain alone versus in complex with 3E6 were accomplished
with PROPKA.60 This revealed that most of the significant perturbations (>0.25 pH units)
occurred in residues composing the 3E6 epitope, which is unsurprising given the
interactions these residues make with the antibody. Only two residues, His2269 (-0.4 pH
units) and His2315 (-0.6 pH units), near the G99 epitope exhibited significant pKa
perturbations. This indicates a weaker case for pKa changes as the basis of cooperativity
than dynamic changes (see below), although it is not ruled out entirely.
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Table 3. PKa changes upon binding. Examples of pKa changes of ionizable groups in C2
alone versus in the C2:3E6 binary complex predicted using PROPKA.60
Residue
Location
pKa Change
Glu2182
3E6 Epitope
2.6
Glu2322
3E6 Epitope
1.3
Lus2183
3E6 Epitope
-2.4
His2211
3E6 Epitope
-1.2
Arg2215
3E6 Epitope
1.8
His2269
G99 Epitope
-0.4
His2315
G99 Epitope
-0.6

To explore the possible contributions of dynamics to the cooperativity question, an
examination of B-factors was undertaken. As mentioned previously, B-factors can be
used to describe the dynamic mobility of atoms in a structure. In order to compare Bfactors between multiple structures of the fVIII C2 domain, however, normalization to
the overall B-factors for each structure was necessary, as B-factors are crystaldependent. To this end, averages were determined for the localized B-factors of each
loop and then divided by the previously described “average B” value for each structure.
This process was undertaken for C2 domain loops from C2:3E6 binary complexes 1 and
2, the C2:3E6:G99 ternary complex, the C2:BO2C11 complex, and isolated the C2
domain.
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Figure 12. Graph depicting variation in B-factors amongst different fVIII C2 domain
structures. Key: Purple, C2 alone; orange, ternary complex; red, binary Complex 1;
green, binary Complex 2; blue, BO2C11.

As expected, B factors for the loops composing the C2:3E6 interface were lower than
the corresponding values for C2 alone (Figure 12). For the Gln2213-Ser2216 loop, an
average of the B factor ratios from the binary and ternary complexes was 0.91 versus
1.50 for isolated C2 domain (Table 2). This loop also partially composes the epitope of
classical antibody BO2C11 and has a likewise reduced B factor ratio value from that
structure of 0.88. Similarly, the second major loop of the 3E6 epitope, Glu2181-Gln2189,
upon antibody binding has a B factor ratio of 0.81 (averaged from the binary, ternary,
and BO2C11 complexes) versus 1.07 for the C2 domain alone. Thus, we see that the B
factors of loops involved in antibody binding are generally lower than those of the C2
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alone, which agrees with the loss of dynamic motion following binding. Interestingly,
three loops that partially compose the G99 epitope, Ser2265-Trp2271, Phe2275Lys2279, and Val2223-Glu2228, also display lowered B factor ratios in the C2:3E6 binary
complex structure. As revealed by the C2:3E6:G99 ternary structure, one residue in
particular, Lys2227, is key to the binding of G99 to C2. The loop that contains this
residue, Val2223-Glu2228, has calculated B factor ratios of 0.83, 0.99, and 1.08,
respectively, for the ternary complex, binary complex 1, and binary complex 2, while the
value calculated for C2 alone was 1.23.

Table 4. B-factor ratios for comparison of B-factors at different epitopes amongst
multiple C2:antibody protein complexes.

One other loop of note that had lowered B factor ratios was Thr2197-Ala2201, which,
while not part of either the 3E6 or G99 epitope, is both a key component of the BO2C11
epitope and is suggested as important for membrane binding. Furthermore, a previous
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study found, via H-D exchange data, that this loop has increased protection factors upon
3E6 binding.61 Subsequently, it seems reasonable to propose that 3E6 binding decreases
dynamic mobility of not only loops comprising the 3E6 epitope, but also loops present
as other regions of the C2 domain surface that are involved in non-classical antibody
interactions and membrane binding. The decrease in dynamic motion of these loops
upon 3E6 binding may serve to lower the entropic cost of binding a second antibody,
thus providing a basis for the cooperative binding noted between 3E6 and G99.
Ultimately, while questions still exist with regards to this cooperative nature, the
elucidation of structures such as C2:3E6 will hopefully provide a greater wealth of
knowledge for understanding the complex fVIII-antibody interactions and lead to the
development of improved therapeutics for patients suffering from hemophilia A.
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Part II Introduction: FVIII and vWF
As noted in the first part of this document, recent X-ray crystal structures have helped
elucidate the complex interactions between fVIII and inhibitory antibodies, while also
allowing for greater refinement of the proposed mechanism of the fVIII C2 domain's
membrane binding role. However, one piece of the fVIII puzzle that still remains poorly
understood is detailed information about the interactions of fVIII with its circulatory
partner, von Willebrand factor (vWF). Interestingly, it has been noted in some studies
that plasma-derived fVIII concentrates containing vWF resulted in lower levels of
inhibitory antibody response in patients receiving these infusions.62-64 This indicates a
protective effect on fVIII by vWF, possibly stemming from the masking of epitopes by
the presence of vWF.65,66 While there is still intense debate over the merits of plasmaderived versus recombinant fVIII with regards to immune tolerance,34 intriguing
questions remain over the role of vWF and its interactions with fVIII. Detailed structural
information about the binding of vWF to fVIII would be a helpful tool in elucidating the
interactions between these two proteins.

In addition, the fVIII-vWF pairing is at the heart of another bleeding disorder that, while
not as prominent as hemophilia A, is the most common inherited bleeding disorder in
the world: von Willebrand's disease (vWD).67,68 In this disorder, which often manifests
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with significantly more mild symptoms than hemophilia, the blood fails to clot properly
due to a lack of vWF in the body.69-71 In severe cases, vWD can be mistaken for
hemophilia A, as the lack of vWF can lead to dangerously low plasma levels of fVIII, since
this protein is rapidly degraded by proteases when not bound to vWF in circulation. 72,73

von Willebrand's disease was first described in the 1920s by Finnish physician Erik von
Willebrand, for whom it was later named. von Willebrand characterized the disease
after studying the case of a young girl from Finland's Aland islands whose family had an
extensive history of hemorrhagic issues.74 The isolated nature of the island population
meant that there was a high incidence of this inherited disease, which is autosomal
recessive, unlike hemophilia A, and thus equally affects men and women. Today, it is
believed that vWD affects anywhere from 1 in 100 to 1 in 1000 individuals, though many
will never know they have the disease because the symptoms are so mild.67 For most
cases, the primary treatment is the on-demand administration of desmopressin, which
stimulates the release of vWF.75 In the event of severe bleeds, however, IV infusions of
vWF are often necessary.

There are three different types of vWF, depending on whether the disorder is
quantitative or qualitative in nature. Type 1 vWD is a quantitative disorder in which the
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body produces abnormally low levels of vWF. It is the most common form of the
disease, accounting for approximately 75% of cases and is generally mild.76 The third
form, Type 3 vWD is also a quantitative disorder, in which the individual is homozygous
for the defective gene, and the body fails to produce any vWF, subsequently leading to
extremely low levels of fVIII.77 It is the rarest form of the disease but also the most
severe. The second form, Type 2 vWD, is a qualitative disorder that has 4 subcategories:
2A, 2B, 2M, and 2N.78 Each of these subcategories is caused by a different gene
mutation that affects vWF's ability to associate with its various binding partners. Type
2N, or the Normandy type, is caused by the inability of vWF to bind to fVIII, thus leading
to hemophilia A-type levels of fVIII in circulation.

von Willebrand Factor
von Willebrand factor (vWF) is a 2,050 residue glycoprotein that is produced in
endothelial cells and megakaryocytes.79,80 It is initially synthesized as a 2,813 residue
product that contains a 22 amino acid signal peptide and 741 residue propeptide that is
eventually removed by proteolytic cleavage in the Golgi apparatus.81 Characterization of
the domains from early cDNA sequence work gives the arrangement of D1-D2-D'-D3-A1A2-A3-D4-B1-B2-C1-C2-CTCK (Figure 13).82-87 However, more recent examination of
sequence and structure relationships indicates that the protein is highly mosaic with
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complex assemblies of modules lacking hydrophobic cores but connected through
extensive disulfide bonding.88 The three A domains, which are the only domains without
an abundance of cysteines, have been thoroughly characterized and their structures
determined, revealing them to be large and globular. The D domains are now
understood to consist of smaller modules, denoted as vWD domains, cysteine-8 (C8)
domains, trypsin-inhibitor-like (TIL) domains, and E domains, based on sequence and
structural homology studies.88 The B and C domains have been re-categorized as 6
tandem von Willebrand C (VWC) and VWC-like domains, and are followed by the cterminal cysteine knot (CTCK) domain, which is homologous to the cysteine knot
superfamily of proteins.88

Figure 13. Domain arrangement of vWF. The upper row of each half depicts the original
domain notation of D1-D2-D’-D3-A1-A2-A3-D4-B-C1-C2-CK. Below these domains is the
new domain notation as described by Zhou et al. following structural studies.88

Upon entry into the endoplasmic reticulum early in their life cycle, provWF monomers
form "tail-to-tail" dimers through disulfide linkages between their CTCK domains.89,90
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Then, following extensive glycosylation that is proposed to occur prior to the
dimerization step, the provWF dimers are then transported to the Golgi apparatus
where they undergo sulfation of oligosaccharides at Asn384 and Asn468, additional
glycosylation, and proteolytic cleavage of the propeptide (domains D1 and D2). 81,91,92
They then undergo extensive multimerization through "head-to-head" disulfide linkages
involving their D3 domains, and can form large multimers that are greater than 20,000
kDa in size.81 These large multimers are necessary for proper vWF function. While some
vWF is secreted constitutively, the rest is stored in granules in endothelial cells called
Weibel-Palade bodies until release upon vascular injury.93

Figure 14. Depiction of vWF’s role in blood clotting. Large vWF multimers help recruit
platelets to the site of vascular injury.
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vWF is not an enzyme but instead performs a number of functions through binding to
other proteins. In the event of injury, vWF binds to subendothelial collagen through its
A3 (and possibly A1) domain and once immobilized then binds inactive platelets under
conditions of high fluid sheer stress (Figure 14).94-97 It binds these platelets through
interaction of the A1 domain with the platelet glycoprotein (GP) Ib receptor complex
and thus recruits them to the site of damage.98 Additionally, vWF can also bind to
activated platelets through the integrin αIIbβ3 binding to its C1 domain.99

Aside from platelet adhesion at the site of vascular injury, vWF also plays another key
role in the blood coagulation process by serving as the circulatory partner of fVIII and
preventing its breakdown in circulation. It is estimated that 95% of fVIII in circulation is
in complex with vWF, which protects it from proteolytic degradation and is also thought
to prevent premature association with fIXa and activated platelet surfaces.100,101 The
importance of this interaction is highlighted by the severity of Type 3 and Type 2N vWD,
in which the body produces normal fVIII levels but often maintains fVIII concentrations
in the blood at near hemophilia A levels due to the inability of fVIII to bind vWF.

The primary binding fVIII binding site on vWF was located to the N-terminal 272 residues
by Foster et al. in 1987 and was further confirmed to be harbored in the D'D3 domains
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in following studies.15,17 Recent evidence suggests that the D' domain, which is itself
composed of two regions, the trypsin-inhibitor-like, or TIL', and E' domains, is primarily
responsible for binding to fVIII.102 Epitope mapping studies using anti-vWF monoclonal
antibodies, as well as the fact that 72% of missense mutations leading to Type 2N vWF
are located in the TIL' domain, make a strong case for this as the primary binding
site.103,104 Furthermore, a recent solution structure of the TIL'E' domains by Shiltagh et
al. provides additional evidence, with the authors proposing a binding model in which
positive charge in the TIL' region, supported by an inflexible scaffold of the E' region and
rigid TIL' β-sheets, forms electrostatic attractions with the acidic region of the fVIII A3
domain that has been demonstrated to be critical for vWF binding (Figure 15).102 This
acidic region, along with the C2 domain, have been shown to comprise the primary vWF
binding site on fVIII.17,105,106
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Figure 15. Solution structure of the TIL'E' domains, which are suggested to harbor the
primary fVIII binding site on vWF.102 These domains are also known collectively as D’.

Despite this evidence, however, no structures exist depicting fVIII bound to vWF. The
complex arrangement and high cysteine content of vWF has stymied acquisition of
detailed structural information for all but the A domains of the protein. In this study, we
attempt co-crystallization of fVIII in complex with the D'D3 domains and with the
smaller binding fragment D’, which will be hereafter referred to by the new naming
convention of TIL’E’ when referred to in isolation (not part of the D’D3 fragment).
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Part II: Research Aims
The goals of this research were threefold. First, we aimed to express and purify the vWF
TIL’E’ (D’) domain for use in structural studies with fVIII and domain mutants thereof.
Following purification, we proposed to form complexes between TIL’E’ and fVIII,
between TIL’E’ and the fVIII C2 domain, and between TIL’E’ and an 18-residue
oligopeptide corresponding to a region of the fVIII a3 domain thought to be essential for
fVIII:vWF binding. Furthermore, we aimed to form these complexes with a second,
larger vWF domain fragment, D’D3, in place of the TIL’E’ to further elucidate fVIII:vWF
binding. To confirm formation of these complexes, affinity pull-down assays were
devised, supplemented by enzyme-linked immunosorbent assays (ELISA) to further
assess binding.

The third aim of this research was to employ X-ray crystallography to study binding
interactions between fVIII and the vFW domain fragments. To this end, X-ray crystal
trials were initiated through the application of hanging-drop vapor diffusion.
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PART II: Materials and Methods

Buffers
TIL'E’ Wash Buffer: 20 mM Tris-HCl (pH 7.5), 500 mM NaCl, 40 mM imidazole

TIL'E’ Elution Buffer: 20 mM Tris-HCl (pH 7.5), 500 mM NaCl, 200 mM imidazole

TIL'E’ Storage Buffer: 20 mM Tris-HCl (pH 7.5), 100 mM NaCl, 2.5% glycerol

FVIII Storage Buffer: 20 mM HEPES (pH 7.5), 5 mM CaCl2, 350 mM NaCl

D'D3 Storage Buffer: 25 mM Tris-HCl (pH 8.0), 100 mM NaCl
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Expression of TIL'E
A pET32b+ vector encoding the TIL'E' domain of vWF was acquired from the Hanson lab
of University College, London. The plasmid also encoded an N-terminal thioredoxin
(TRX) tag and N-terminal internal (His)6-tag, separated from the coding region by a 31residue linker and tobacco etch virus (TEV) protease cleavage site. The vector was
transformed into New England Biosciences SHuffle® cells, and colonies were selected
from ampicillin selection plates for large-scale expression. Ten mL Luria Bertani (LB)
broth (10% (w/v) BactoTryptone, 5% (w/v) yeast extract, 10% (w/v) NaCl) cultures
containing 50 mg/mL ampicillin (AMP) were inoculated from selected colonies and
allowed to grow overnight at 37°C. These starter cultures were then used to inoculate 1
L LB/AMP cultures, which were grown at 37°C until an OD600 reading of 0.6 was reached
and then induced with 0.4 mM isopropyl β-D-1-thiogalactopyranoside (IPTG). The
temperature was lowered to 15°C and cultures were allowed to grow overnight with
shaking. The following day, cells were pelleted by centrifugation at 6,300 x g for 10
minutes in a Sorvall GS-3 rotor (Du Pont Instruments) and stored at -20°C until
purification.
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Affinity Chromatography Purification of TIL'E
Cell pellets were resuspended in 30-mL TIL'E' wash buffer. Lysozyme and
phenylmethanesulfonyl fluoride (PMSF) were added to final concentrations of 1 mg/mL
and 1 mM, respectively, and the solution was incubated with gentle agitation for 30
minutes at 4°C. Cells were then lysed via sonication in two 45-second intervals (Branson
sonifer, 50% duty cycle). The lysate was centrifuged at 36,000 x g for 40 minutes in a
Sorvall SS-34 rotor (Du Pont Instruments) to pellet insoluble cell debris, and the
resulting supernatant was filtered prior to chromatography through successive 5 µm
and 0.45 µm filters. HisPurTM Ni-NTA affinity resin (Thermo Scientific) was preequilibrated in TIL'E' wash buffer prior to incubation with the filtered lysate for one hour
with stirring at 4°C. The solution was then applied to a gravity flow column, and the
resin washed with 10 column volumes (cv) of TIL'E' wash buffer. (His)6-tagged TIL'E' was
eluted using with TIL'E' elution buffer, with successive 2-mL fractions monitored for
presence of protein using Bradford reagent. Fractions were then pooled and dialyzed
into TIL'E' storage buffer overnight at 4°C using 12-14 molecular weight cut off (MWCO)
dialysis tubing (Spectrum Laboratories, Inc.).
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TEV Cleavage
Tobacco etch virus (TEV) protease was used to cleave the TRX-(His)6-tag-linker fragment
from the TIL'E' domain prior to further studies. A ratio of 1 OD280 unit TEV to 5 OD280
units TIL'E' was utilized for the cleavage reactions. Samples containing (His) 6-tagged TEV
and TIL'E' were incubated at room temperature for three hours prior to overnight
incubation at 4°C. The following day, samples were applied to a gravity flow column
containing Ni-NTA affinity resin pre-equilibrated in TIL'E' wash buffer and incubated for
30 minutes to encourage binding of (His)6-tagged TEV and cleavage fragments to the
metal ions. The initial flow through and 5-mL wash with TIL'E' wash buffer were
collected prior to washing the column with TIL'E' elution buffer. A fraction of this eluent
was collected for SDS-PAGE analysis to determine of cleavage efficiency. The initial
fractions collected were buffer-exchanged into TIL'E' storage buffer and concentrated
using an Amicon Ultra-15 Centrifugal filters (Ultracell 10K membrane, Millipore) prior to
SDS-PAGE analysis.

SEC of TIL'E'
As a final purification step, cleaved TIL'E' was applied to a HiLoadTM 16/60 Superdex 75
preparatory grade size exclusion chromatography column (120 mL column volume, GE
Healthcare). The column was pre-equilibrated in TIL'E' storage buffer and attached to an
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ӒKTAprime Plus compact liquid chromatography system (GE Healthcare). TIL'E' eluent
and impurity peaks were collected for SDS-PAGE analysis.

Binding Assay
To assess the binding of the vWF TIL'E' and D'D3 domains to fVIII, an affinity resin pulldown assay was employed. A 100 µL sample containing 50 ug of (His) 6-tagged TIL'E' or
D'D3 and an equimolar ratio of fVIII ET3 in TIL'E' or D'D3 storage buffer was incubated at
room temperature for 15 minutes. This sample was then incubated for 10 minutes at
room temperature with 100 µL of 50% HisPurTMNi/NTA resin (Thermo Scientific) slurry
equilibrated in TIL'E' or D'D3 storage buffer. Following incubation, the sample was
transferred to a Costar Spin-X® centrifuge tube filter (Corning Incorporated) and
centrifuged at 500 x g for 1 minute. The initial flow through was collected prior to the
resin being washed 2X for 1 minute intervals at 500 x g with 250 µL of storage buffer.
Protein was then eluted in an additional centrifugation step with 100 µL TIL'E' elution
buffer. Flow through, wash, and elution samples were then analyzed via SDS-PAGE.

Formation of vWF:fVIII Complexes
Purified TIL'E' or D'D3 was mixed with fVIII ET3 in a 1.5:1 molar excess of the vWF
domain to fVIII. Samples were incubated at room temperature for 15 minutes to
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encourage complex formation. Complexes were then concentrated to >1 mg/mL using
Pierce 3K MWCO concentrators (Thermo Scientific) for X-ray crystallography trials.

X-ray Crystal Trials
Hanging drop vapor diffusion was selected to crystallize the fVIII:D'D3 or fVIII:TIL'E'
complexes. Initial screening for suitable crystallization conditions was achieved with
sparse matrix screens from Hampton Research and Rigaku Reagents. In this method,
400 µL of each condition was pipetted into the reservoirs of 24-well plates. One µL of
well solution was placed on a glass cover slide and mixed with 1 µL of protein complex.
The cover slide was then immediately placed over the well, which was pre-greased to
provide a strong seal upon placing of the slide. Trays were left undisturbed for 24-hours
to allow vapor diffusion to take place prior to checking for the presence of crystal
formation. Initial hits from sparse matrix screens were optimized by varying pH, salt,
precipitant, and protein: mother liquor ratios in order to grow larger and more welldefined crystals for diffraction.

Enzyme-linked Immunosorbant Assays (ELISA)
Purified fVIII, fVIII:D'D3, or fVIII:TIL'E' was incubated in rows A-C and E-G of 96-well
plates for 45 minutes at 37°C. Plates were then rinsed 3X with 1X Tris-buffered saline
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(TBS) solution. Rinsed plates were blocked with 3X bovine serine albumin (BSA) for 1
hour at 37°C and again rinsed 3X in TBS. From starting samples of 1200 nM, twelve part
serial dilutions of 3E6 and G99 IgG were made in 1% (w/v) BSA/TBS and plated in rows
A-D and E-H, respectively, in the blocked and rinsed plates. Plates were then incubated
at 37°C for 90 minutes, prior to rinsing 3X in TBS. Goat anti-mouse 2° antibody
conjugated to alkaline phosphatase (AP) (Kirkegaard and Perry Laboratories, Inc.) was
diluted 1:2000 in 1X TBS and was then incubated in all wells for 30 minutes at 37°C
before a final rinsing step (3X in 1X TBS). AP substrate p-nitrophenyl phosphate (pNPP)
was then added to all wells and incubated for approximately 5 minutes at 37°C prior to
reading absorbance at 405 nm on a BioTek Epoch plate reader.

FVIII Acidic Region Peptide Binding Assays
To assess binding to the vWF domain fragments and act as a crystallization aid, an 18residue peptide of the sequence MKKEDFDIYDEDENQPRS, corresponding to residues
1691-1709 of fVIII was constructed. This peptide was produced by solid phase peptide
synthesis in the Antos Lab of Western Washington University, and contained an Nterminal biotin tag for experimental purposes. To test binding of this construct to vWF
domain fragments TIL’E’ and D’D3, a simple resin binding assay similar to that reported
above was utilized. Following a 15 minute, room temperature incubation of a 1:1 ratio
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of peptide and either D’D3 or TIL’E’, 100 µL of streptavidin-agarose resin (50% slurry,
Thermo Scientific) was added to the sample and incubated with gentle agitation for 10
minutes at room temperature to encourage binding. These samples were then added to
spin filters and centrifuged as described previously, with initial flow through, two wash,
and elution fractions collected for SDS-PAGE analysis.
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Part II: Results and Discussion
Preparation of Pure TIL'E' Domain
For X-ray crystallography studies, a relatively large amount of purified protein (10-100
mg) is required. To this end, expression and purification of the vWF TIL'E' domain was
initiated. A bacterial expression system was utilized, with transformation of the TIL'E'
plasmid into the New England Biosciences SHuffle E. coli line. This cell line is engineered
to aid in the proper folding of disulfide-bonded proteins in the cytoplasm of the cell,
containing a mutation that allows for the constitutive production of disulfide bond
isomerase DsbC.107 Additionally, to encourage the proper folding of disulfide bonds
within the TIL'E' domain, the TIL'E' plasmid contains an N-terminal thioredoxin (TRX)
protein tag (Figure 16).

TRX

His6-tag

31-residue linker

TEV

TIL’E
’

Figure 16. Schematic depicting arrangement of the TIL’E’ (D’)-TRX fusion protein
encoded by the pET32b(+) vector. TRX, thioredoxin tag; His6-tag, hexahistidine tag; TEV,
tobacco etch cleavage virus protease cleavage site.

Following protein expression, three column chromatography steps were utilized to
ensure sufficient purity for crystal trials. The initial Ni/NTA affinity chromatography step
takes advantage of the internal (His)6-tag encoded by the pET15b(+) vector to separate
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the majority of impurities from the TIL'E' domain (Figure 17). This was followed by
removal of TRX and the (His)6-tag by tobacco etch virus (TEV) protease cleavage.
Another Ni/NTA chromatography step was used to remove the (His)6-tagged TEV, TRX(His)6-tag-linker fragment, and any uncleaved TIL'E' from the purified fraction (Figure
18). Finally, to remove trace impurities, a final size-exclusion chromatography step was
employed (Figure 19).
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Figure 17. SDS-PAGE analysis of TIL’E’ (D’) protein purity following initial affinity metal
chromatography purification step. Lanes: 1. Molecular weight marker; 2. Filtered lysate;
3. Insoluble fraction; 4. Initial column flow through; 5. Column wash; 6. Elution fraction.

Following each column chromatography step, the purity of the protein was assessed by
SDS-PAGE. Prior to cleavage of the tags, the TIL'E' fusion protein migrates near 27 kD.
After the cleavage step, the final mass of the TIL'E' domain alone is 11 kD. While
contaminating bands are seen on all of the gels following initial purification steps, after
the final SEC step, a single band at the expected molecular weight for TIL’E’ is present.
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Figure 18. SDS-PAGE analysis following TEV cleavage of TIL’E’ (D’). Lanes: 1. Molecular
weight marker; 2. Uncleaved TIL’E’; 3. TEV + TIL’E’; 4. Ni/NTA wash fraction; 5. Ni/NTA
elution fraction.

Figure 19. Analysis of TIL’E’ (D’) purity following size-exclusion chromatography. Left,
elution profile of TIL’E’. Right, SDS-PAGE after chromatography step. Lanes: 1. Molecular
weight marker; 2; Pre-SEC TIL’E’ sample; 3. Pooled impurity peaks fraction; 4. TIL’E’
peak.
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Formation of fVIII:TIL'E' and fVIII:D'D3 Complexes
The fVIII:TIL'E' and fVIII:D'D3 complexes were formed by incubation of a 1.25:1 ratio of
vWF domain: fVIII for 15 minutes at room temperature. Due to the large size of the
complex, it was not an ideal candidate for in-house size exclusion chromatography, as it
would elute in the void volume of the HiLoadTM 16/60 Superdex 75 preperatory grade
size exclusion chromatography column. Therefore, we devised a simple assay to confirm
binding of the vWF domains to fVIII. Taking advantage of the (His)6-tag present on both
TIL'E' and D'D3 prior to cleavage, a Ni/NTA affinity pull-down protocol was developed, in
which a sample containing fVIII complexed with tagged-vWF domain was incubated with
Ni/NTA resin and then centrifuged. Initial flow through, wash, and elution fractions were
checked for the presence of proteins by SDS-PAGE. The fVIII and vWF domains were
present in the elution fraction, indicating that the fVIII bound to the tagged D'D3 or
TIL'E' and was not simply washed away in the initial flow through or subsequent washing
steps (Figure 20).
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Figure 20. SDS-PAGE gels from FVIII/vWF binding assays. Left, binding of fVIII to affinitytagged TIL’E’ domains. Lanes: 1. Molecular weight marker; 2. fVIII; 3. TIL’E’; 4. Initial flow
through; 5. Wash #1; 6. Wash #2; 7. Elution. Right, binding of fVIII to affinity-tagged
D’D3 domains. 1. Molecular weight marker; 2. fVIII; 3. D’D3; 4. Initial flow through; 5.
Wash #1; 6. Wash #2. 7. Elution.

Attempt to Form HC2:TIL'E' and HC2:D'D3 Complexes
Previous studies have indicated that while the primary vWF binding site on fVIII consists
of both the acidic region of the fVIII light chain and the C2 domain, the C2 domain alone
can bind to full-length vWF with a 564 nM affinity.17 As the primary fVIII binding site on
vWF has been located to the N-terminal D'D3 region, we wanted to assess the binding of
the human fVIII C2 domain to the D'D3 fragment and to TIL'E'. The same Ni/NTA affinity
pull-down assay was utilized as described above, but with (His)6-tagged C2 and untagged
D'D3 or TIL'E' (Figure 21). The results of this assay were somewhat inconclusive. In only
one of the five trials with C2:TIL’E’ was TIL’E’ detected in the elution profile; in all
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remaining trials it was seen instead in the initial flow through step. The C2:D’D3 complex
had similar results, in which only one of the trials indicated that binding had occurred.
This indicates that the binding interaction between C2 and TIL'E' or D'D3 was often not
sufficiently strong to survive the centrifugation step, as weak binding was seen only
infrequently in the repetitions of the assay.
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Figure 21. SDS-PAGE analysis of C2 binding to D’D3. Lanes: 1. Molecular weight marker;
2. C2; 3. D’D3; 4. Initial flow through; 5. Wash #1; 6. Wash #2; 7. Elution.

Following this initial result, size exclusion chromatography was utilized to assess
binding. Following a 30 minute incubation at room temperature to encourage complex
formation, C2:TIL'E' (not shown) or C2:D'D3 was applied to a size exclusion
chromatography column but repeatedly failed to co-elute (Figure 22). We were not able
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to form stable C2:TIL’E’ or C2:D’D3 complexes for crystallographic studies based on the
methods of detection we had at our disposal.

SEC Elution Profile of D'D3:C2 Complex
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Figure 22. Analysis of C2:D’D3 binding. Left, size-exclusion chromatography elution
profile following attempt to form C2:D’D3 complex. Right, SDS-PAGE analysis of SEC
peaks. Lanes: 1. Molecular weight marker; 2. D’D3; 3. C2; 4. First peak; 5. Second peak.

FVIII Acidic Region Peptide
As noted above, previous studies have identified the fVIII acidic region as partially
comprising the vWF binding site. Particularly, residues 1669-1689 of the a3 region have
been shown to be a strong determinant for binding.17 To investigate this interaction, a
biotinylated 18-residue peptide was synthesized, consisting of residues 1671-1689. As
peptides have been shown to be aids for crystallization of proteins resistant to
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formation of crystals, it was hoped that formation of a complex between the peptide
and the D’D3 or TIL’E’ domains would encourage these proteins to crystallize.

To test binding of the peptide to the vWF domains, a simple resin binding assay was
utilized. This assay took advantage of the N-terminal biotin tag present on the peptide,
as biotin forms a very strong interaction with streptavidin. Using streptavidin-agarose
resin in place of Ni/NTA, a binding assay similar to those described previously was
employed for probing peptide:D’D3 or peptide:TIL’E’ binding (Figure 23). Surprisingly,
the vWF domains were seen in the initial flow through and wash fractions, and failed to
be detected in the sample containing the streptavidin-agarose beads, even though
association of the peptide with streptavidin using biolayer interferometry (BLI)
measurements indicated that the biotin tag was binding as expected. This result
indicates that the acidic region peptide is not sufficient for binding to these isolated vWF
fragments strongly enough to be detected by an affinity pull-down assay.
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Figure 23. SDS-PAGE analysis of lack of binding of fVIII acidic region peptide to D’D3.
Lanes: 1. Molecular weight marker; 2. D’D3; 3. Initial flow through; 4. Wash #1; 5. Wash
#2; 6. Elution.

ELISA
To probe the interaction between fVIII and the vWF domain fragments, enzyme-linked
immunosorbent assays (ELISAs) were undertaken. Studies focused on immune tolerance
induction (ITI) as a therapy for hemophilia A have suggested that vWF plays a protective
role in abrogating the immune response of inhibitory antibodies generated against fVIII.
As discussed in the introduction, two inhibitory antibodies against fVIII, classical
antibody 3E6 and non-classical antibody G99, have been shown to target the C2 domain.
As the C2 domain is implicated as a part of the vWF binding site on fVIII, we were
interested in what effect the presence of D'D3 or TIL'E' would have on the binding of
either 3E6 or G99 to fVIII. In the ELISA assays, the fVIII:TIL'E' or fVIII:D'D3 complex was
adhered to the 96-well plate, followed by incubation with 3E6 or G99 IgG. A secondary
64

antibody, conjugated to alkaline phosphatase, targeting the Fc region of the IgGs was
then used for detection of IgG binding.

Both G99 and 3E6 IgGs were able to bind fVIII even in the presence of D’D3 or TIL’E’
(Figure 24). In the presence of TIL’E’, the binding dissociation constant, or Kd, was 2.3
nM for the 3E6 IgG and 1.4 nM for the G99 IgG. These values are comparable to those of
the IgGs binding to FVIII alone, which were 2.3 nM and 2.8 nM, respectively, for 3E6 and
G99. Similar numbers were obtained for the presence of D’D3. For the 3E6 IgG, a K d
value of 3.8 nM was found, whereas the G99 IgG had a Kd of 0.66 nM. Thus, while small
variations in the Kd values were noted, no significant reduction in IgG binding was seen
in the presence of the vWF domains.
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Figure 24. ELISA data of IgG binding to fVIII in the presence of TIL’E’ (D’) or D’D3. Top,
no vWF domains. Middle, IgG binding to fVIII:D’D3 complex. Bottom, IgG binding to
fVIII:TIL’E’ complex. Open circles: fVIII + 3E6, solid squares: fVIII + G99. Each figure is the
result of two repeated experiments completed in triplicate.
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Binding of FABs to fVIII in Presence of vWF Domains
Following these ELISA results comparing the FAB binding to fVIII in the presence of vWF
domains, we were interested in confirming this outcome using another method. We
employed resin binding assays as described previously but with one additional step:
following the incubation of fVIII with either TIL’E’ or D’D3, G99 or 3E6 FAB was added to
the sample in a 1:1 molar ratio with fVIII. The sample was then incubated at room
temperature for 15 minutes before addition of the Ni/NTA resin and subsequent
centrifugation steps. The presence of SDS-PAGE gel bands corresponding to the FABs in
the elution step indicates that, regardless of the presence of TIL’E’ or D’D3, the
antibodies are still able to bind fVIII (Figures 25 and 26). This corroborates the findings
from the ELISA assays.

Figure 25. SDS-PAGE analysis of binding of FABs to fVIII in the presence of TIL’E’ (D’). Left,
binding of 3E6 FAB to fVIII. Lanes: 1. Molecular weight marker; 2. fVIII; 3. TIL’E’; 4. 3E6; 5.
Initial flow through; 6. Wash #1; 7. Wash #2; 8. Elution. Right, binding of G99 FAB to fVIII.
Lanes: 1. Molecular weight marker; 2. fVIII; 3. TIL’E’; 4. G99; 5. Initial flow through; 6.
Wash #1; 7. Wash #2; 8. Elution.
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Figure 26. SDS-PAGE analysis of binding of FABs to fVIII in the presence of D’D3. Left,
binding of 3E6 FAB to fVIII. Lanes: 1. Molecular weight marker; 2. fVIII; 3. D’D3; 4. 3E6; 5.
Initial flow through; 6. Wash #1; 7. Wash #2; 8. Elution. Right, binding of G99 F AB to fVIII.
Lanes: 1. Molecular weight marker; 2. fVIII; 3. D’D3; 4. G99; 5. Initial flow through; 6.
Wash #1; 7. Wash #2; 8. Elution.

X-ray Crystal Trials
X-ray crystallography provides a powerful tool for elucidating the structural interactions
in protein complexes. To examine the interactions in fVIII:vWF binding more thoroughly,
X-ray crystal trials involving the fVIII:D'D3 complex and fVIII:TIL'E' complex were
initiated. Over 2,000 sparse matrix conditions were screened for each complex. Table 3
identifies the screens used to identify initial crystal leads, purchased from Hampton
Research and Rigaku Reagents.
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Table 5. List and brief descriptions of sparse matrix screens utilized for crystallization
attempts of fVIII complexes.

Screen

Manufacturer Description

Crystal Screen

Hampton
Research

Index

Hampton
Research

PEG/Ion

Hampton
Research

PEG Rx

Hampton
Research

Crystal Screen
Cryo

Hampton
Research

Wizard Classic

Rigaku Reagents

Precipitant
Synergy

Rigaku Reagents

PEGs Suite

Quiagen

Primary, highly diverse sparse matrix
screen, utilizing a wide variety of salts
and precipitants over a wide pH range.
Primary, highly diverse sparse matrix
screen, utilizing a wide variety of salts
and precipitants over a wide pH range.
Sparse matrix screen evaluating range
of salt conditions with monodisperse
polyethylene glycol precipitants.
Sparse matrix screen evaluating
different polymer precipitants over a
wide pH range.
Sparse matrix screen evaluating range
of buffers and salts against
cryoprotectants, including glycerol,
PEG 400, and others.
Primary, highly diverse sparse matrix
screen, utilizing a wide variety of salts
and precipitants over a wide pH range.
Sparse matrix screen utilizing multiple
precipitants simultaneously in a single
condition to encourage crystallization
in difficult protein targets.
Sparse matrix screen employing a
wide pH range with low salt
concentrations against a variety of
polyethylene glycol polymers as
precipitants.
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FVIII: TIL'E' Complex
The fVIII: TIL'E' complex yielded multiple leads from sparse matrix conditions. In each of
these cases, the crystals were generally flat and diamond-shaped in appearance, lacking
the 3-dimensionality needed for successful diffraction (Figure 27). Additionally, the
more 3D crystals were composed of thin, overlapping sheets, as opposed to a single,
thick layer. Four of these conditions were selected for optimization to encourage growth
of larger crystals with better morphology for diffraction (Table 4). The optimization
process generally consists of varying two components of the crystal conditions, one in
the 24-well plate’s X-direction and one in the Y-direction, while keeping the others
constant. Frequently, these changes involve altering the concentration or identity of a
salt, precipitant, or buffer component. For example, a common strategy is the varying of
the polyethylene glycol (PEG) concentration in the X-direction, while varying the
solution pH in the Y-direction.

Table 6. Sparse matrix conditions yielding leads for fVIII:TIL’E’ (fVIII:D’) complex.

Screen

Manufacturer

Initial Condition

PEG/Ion 2 #35

Hampton Research

PEG/Ion 2 #45
Crystal Screen 2
#30
Index #61

Hampton Research
Hampton Research

2% v/v Tacsimate, 0.1 M Tris (pH
8.5), 16% w/v PEG 3350
0.1 M CsCl, 15% w/v PEG 3350
0.1 M HEPES (pH 7.5), 10% w/v
PEG 6000, 5% v/v MPD
0.2 M proline, 0.1 M HEPES (pH
7.5), 10% w/v PEG 3350

Hampton Research
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Figure 27. Images of fVIII:TIL’E’ (fVIII:D’) complex crystals produced by hanging drop
vapor diffusion.

Following optimization, three crystals, listed in Table 5, were selected for screening at
the Fred Hutchinson Cancer Research Center in Seattle to ascertain if they diffracted.
These crystals were cryoprotected by the addition of 30% DMSO and immediately flash
frozen. Of the three crystals, one diffracted very weakly. While not strong enough
diffraction for the collection of a data set, this result identified the crystals as protein
rather than salt, and indicated that the fVIII:TIL’E’ complex is able to be crystallized,
which is a considerable hurdle in the X-ray crystallography process. At the time of this
71

writing, optimizations of the fVIII:TIL’E’ crystallization conditions are ongoing in the
hopes of producing crystals with stronger diffraction.

Table 7. List of fVIII:TIL’E’ (fVIII:D’) crystals selected for screening at the Fred Hutchinson
Cancer Research Center in Seattle, WA.

Initial
Screen

Optimization Buffer
#

PEG/Ion 2 #35 1
PEG/Ion 2 #35 1
PEG/Ion 2 #45 1

0.1 M TrisHCl (pH 6.9)
0.1 M TrisHCl (pH 7.25)
None

Salt(s)/
Additives

Precipitant

2% Tacsimate
(pH 8.0)
2% Tacsimate
(pH 8.0)
0.05 M CsCl

16% PEG 3350
18% PEG 3350
17% PEG 3350

FVIII: D'D3 Complex
Initial sparse matrix conditions with the fVIII:D’D3 complex yielded less leads than the
fVIII:TIL’E’ complex. None of the seven conditions with initial hits resulted in the
formation of relatively large, distinct crystals as in the fVIII:TIL’E’ trays (Figure 28).
However, two conditions, PEG RX 2 #27 and #43, yielded showers of crystalline
precipitate that were selected for optimization, while 3 conditions, Wizard Screen #3, #5
and #74, resulted in the formation of quasi-crystals, which were circular in shape with
no clearly defined edges. One condition, PEG/Ion 2 #47, produced a single, defined
crystal, but this was not able to be reproduced in following trials. Table 6 lists the initial
leads selected for optimization. While crystallization in all conditions except for PEG/Ion
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2 #47 was able to be recapitulated, none of the conditions yielded significant
improvement in size or morphology of the initial leads. Ongoing optimization is needed
to improve upon initial fVIII:D’D3 complex leads.

Table 8. Sparse matrix conditions yielding hits for the fVIII:D’D3 complex.
Screen

Manufacturer Buffer

PEG/Ion 2
#47
PEG Rx 2
#27
PEG Rx 2
#43

Hampton
Research
Hampton
Research
Hampton
Research

0.05 M HEPES (pH
7.0)
0.1 M Tris-HCl (pH
8.0)
0.1 M HEPES (pH
7.5)

Wizard #3

Rigaku
Reagents
Rigaku
Reagents
Rigaku
Reagents
Quiagen

0.1 M CHES (pH
9.5)
0.1 M CAPS (pH
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Figure 28. Images of crystals obtained in sparse matrix screens of
the fVIII:D’D3 complex
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Conclusions
The importance of fVIII and its interactions with other proteins is exemplified by the
bleeding disorders engendered by its absence. Both hemophilia A and type 2N von
Willebrand's disease present a lifetime's worth of complications for patients, with costly
and inconvenient treatments an unfortunate necessity. Subsequently, better
understanding of the structural basis of fVIII's interactions with both inhibitors and its
circulatory binding partner, von Willebrand factor, is needed in order to move forward
with the development of superior treatments and patient care.

As noted above, recent years have seen an increase in the structural understandings of
fVIII's interactions with inhibitory antibodies. The 2.6 Å resolution structure of the fVIII
C2 domain in complex with classical inhibitory antibody 3E6 further supports the
findings from the recent C2-3E6-G99 ternary structure.52 Comparisons between these
two structures reveal considerable overlap between residues at the C2-3E6 interface,
indicating that the 3E6 epitope on C2 is well-conserved both in the absence and
presence of non-classical inhibitory antibodies. As noted previously for the ternary
structure, the 3E6 FAB appears to occlude residues on the C2 domain thought to be
important for von Willebrand factor binding.
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Interestingly, however, ELISA and resin binding studies indicate that 3E6 is still able to
bind to fVIII in the presence of vWF domain fragments thought to contain the primary
fVIII binding site. Furthermore, while earlier studies have demonstrated that the C2
domain alone is able to weakly bind full-length vWF, the formation of stable complexes
between either D'D3 and C2 or TIL'E' and C2 for X-ray crystallography was not achieved.
Thus, we hypothesized that the role of C2 in the vWF binding site on fVIII was not the
major determinant of stable binding.

The publication of two recent studies involving the binding of vWF to fVIII sheds light on
these findings and indicates an exciting new direction in the field of structural
interactions between fVIII and its binding partner. The first of these studies, by Yee et
al., presents low-resolution cryo-electron microscopy data of the vWF D'D3 domains
binding to fVIII.108 A structure based on 3D reconstruction of these data presents a novel
binding model, in which the D' module of vWF interacts with fVIII via the C1 domain
primarily, as opposed to a connection through the C2 domain (Figure 29). The authors
emphasize the dynamic nature of this interaction, in part due to the inability to fit the
fVIII C domains into the data envelope as readily as the more static A domains. This may
indicate significant conformational changes in the C domains upon binding to vWF. The
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second recent publication involving fVIII-vWF interactions further emphasizes the role of
the fVIII C1 domain in binding. Chiu et al. performed negative-stain electron microscopy
(EM) and hydrogen-deuterium mass spectroscopy (HDX-MS) studies with D'D3 in an
attempt to elucidate the primary vWF binding site on fVIII.109 Their findings corroborate
those of Yee et al. in that the fVIII C1 domain is established as the major vWF binding
site. However, while Yee et al. were unable to definitively establish a role for the acidic
region of the fVIII A3 domain in vWF binding--which had been previously indicated as
critical for fVIII-vWF association--Chiu et al. determined by HDX-MS that structural
perturbations in the a3 region indicate the involvement of these residues in binding.

Figure 29. Model of vWF D’D3 domain binding to fVIII proposed by Yee et al. following
collection of low resolution electron microscopy data.108
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These recent studies support our findings that neither the C2 domain alone nor the
acidic region peptide were sufficient to establish stable complexes with the vWF D'D3
domains. Furthermore, this launches an exciting new direction in the structural studies
of fVIII and vWF, as our focus shifts from the C2 domain alone to the C1 domain and C1C2 multi-domain region. Production of the C1 domain in isolation in bacterial expression
systems has, to our knowledge, thus far not been achieved. However, the expression
system of the pET32b(+) vector in the NEB SHuffle cell line has shown great promise in
production of the previously intractable vWF TIL'E' domain. Therefore, attempts are
underway to utilize this system for the production of isolated C1 and C1-C2 domain
constructs, with the ultimate goal of using X-ray crystallography to elucidate the
detailed structural mechanism by which the FVIII C1 domain binds to vWF and thereby
add to the body of fVIII structural knowledge. While the intricacies of fVIII's interactions
with other proteins in circulation have often eluded researchers, recent structural
findings will hopefully help pave the way for greater understanding of these interactions
and, subsequently, improved therapeutic strategies for patients suffering from fVIIIrelated diseases.
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